SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the
Morgan Stanley Global Healthcare Unplugged Conference on
Wednesday, September 14, 2011 at
1:35 p.m. ET / 10:35 a.m. PT in New
York. Daniel M. Bradbury,
president and chief executive officer, Amylin Pharmaceuticals, will
provide a corporate overview.
The presentation will be webcast live through the "Investors"
section of Amylin's corporate website at www.amylin.com, and a
recording will be made available on the website following the
event. To access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California and has a
commercial manufacturing facility in Ohio. Further information about Amylin
Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.